Osterweis Capital Management Inc. Has $9.26 Million Position in Repligen Corporation $RGEN

Key Points

• Osterweis Capital Management Inc. increased its holdings in Repligen Corporation by 18% in Q1, owning 72,765 shares valued at approximately $9.26 million.
• Repligen's stock has a current market cap of $6.72 billion with revenue growth of 14.8% year-over-year, despite a recent earnings miss.
• Analyst ratings show a consensus of "Moderate Buy" with an average price target of $169.55 after several recent upgrades to buy ratings from various analysts.

Osterweis Capital Management Inc. increased its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 18.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 72,765 shares of the biotechnology company's stock after acquiring an additional 11,080 shares during the period. Osterweis Capital Management Inc. owned about 0.13% of Repligen worth $9,259,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. Alliance Wealth Advisors LLC UT boosted its position in shares of Repligen by 2.5% during the 1st quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company's stock valued at $468,000 after acquiring an additional 89 shares in the last quarter. State of Michigan Retirement System lifted its holdings in Repligen by 0.8% during the 1st quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock valued at $1,585,000 after purchasing an additional 100 shares during the last quarter. Louisiana State Employees Retirement System lifted its holdings in Repligen by 0.7% during the 1st quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company's stock valued at $1,858,000 after purchasing an additional 100 shares during the last quarter. State of Wyoming lifted its holdings in Repligen by 5.2% during the 1st quarter. State of Wyoming now owns 2,338 shares of the biotechnology company's stock valued at $297,000 after purchasing an additional 115 shares during the last quarter. Finally, Signaturefd LLC lifted its holdings in Repligen by 65.3% during the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 128 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Repligen

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of the stock in a transaction dated Friday, August 8th. The stock was bought at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the transaction, the director directly owned 1,800 shares in the company, valued at $201,834. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 1.20% of the stock is currently owned by corporate insiders.

Repligen Trading Down 0.6%

Shares of NASDAQ RGEN opened at $119.51 on Friday. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The company has a 50-day moving average of $121.01 and a two-hundred day moving average of $128.35. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. The company has a market cap of $6.72 billion, a PE ratio of -478.02, a P/E/G ratio of 2.21 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same quarter in the prior year, the firm earned $0.40 EPS. The firm's quarterly revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, equities analysts expect that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Stephens raised shares of Repligen to an "overweight" rating and set a $160.00 price target for the company in a report on Tuesday, July 22nd. HC Wainwright reissued a "buy" rating and set a $180.00 price target on shares of Repligen in a report on Wednesday, September 3rd. Evercore ISI cut their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a report on Tuesday, July 8th. Wall Street Zen downgraded shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Finally, Barclays initiated coverage on shares of Repligen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 target price for the company. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $169.55.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.